新辅助化疗对骨肉瘤组织中β-catenin蛋白表达的影响

目的探讨β—catenin蛋白在新辅助化疗前、后骨肉瘤组织中的表达变化及其与骨肉瘤临床病理特征的关系。方法通过免疫组织化学方法检测54例新辅助化疗前、后骨肉瘤组织，骨样骨瘤11例，骨母细胞瘤7例及反应性新生骨8例组织中β-catenin蛋白的表达，并结合临床资料进行相关分析。结果β—catenin蛋白在大部分骨样骨瘤、骨母细胞瘤及反应性新生骨病例中胞膜正常表达，而在骨肉瘤病例中胞浆（核）异常表达。新辅助化疗前骨肉瘤组织中β-catenin蛋白的异常表达率明显高于骨样骨瘤、骨母细胞瘤及反应性新生骨组织，差异具有统计学意义（P〈0．01）。新辅助化疗前β—catenin蛋白异常表达率在骨肉瘤肺转移组明显高于无肺转移组（P〈0．05）。新辅助化疗后骨肉瘤β—catenin蛋白异常表达较化疗前降低或消失（P〈0．01），其表达与肿瘤坏死率不存在相关性。结论β—catenin蛋白可能成为良、恶性成骨肿瘤鉴别诊断有益的辅助指标。新辅助化疗前β—catenin蛋白高异常表达率与骨肉瘤患者肺转移关系密切。新辅助化疗可降低骨肉瘤组织中β-catenin蛋白的异常表达，可在一定程度上反映新辅助化疗的疗效。

Effect of neoadjuvant chemotherapy on expression of Beta-catenin protein in osteosarcoma

Objective To investigate the expression of beta-catenin in osteosarcoma before and after the neoadjuvant chemotherapy and to explore the relationship between the positive rate of beta-catenin and clinical pathological features. Methods The expressions of beta-catenin protein were detected by immunohistochemical stain in 54 cases of osteosarcoma before and after neoadjuvant chemotherapy, including 11 cases of osteoidosteoma, 7 cases of osteoblastoma and 8 cases of newly formed bone in non - malignant bone disease. Results The membrane localization of beta-catenin was found in osteoidosteoma, osteoblastoma and newly formed bone in non - malignant bone disease group, while translocation of beta-catenin to the cytoplasm and/or nucleus of osteosarcoma cells was detected in osteosarcoma group. The aberrant expression rate of beta-catenin protein in osteosarcoma group was significantly higher than that in osteoidosteoma, osteoblastoma and newly formed bone in nonmalignant bone diseases group （ P 〈 0. 01 ）. The aberrant expression rate of beta-catenin protein in osteosarcoma group with pulmonary metastasis was significantly higher than that in non-pulmonary metastasis group （ P 〈 0.05 ）. The aberrant expression of beta-catenin protein in osteosarcoma group became lower or disappeared after neoadjuvant chemotherapy（ P 〈 0.01 ）. But the expression of beta-catenin had no relationship with tumor cell necrosis rate （TCNR）. Conclusion The aberrant expression rate of beta-catenin in osteosarcoma is significantly higher than that in non - malignant bone tumors. The detection of beta-catenin protein may be a helpful marker in identification of benign and malignant bone tumors. The aberrant expression of beta-catenin protein has close relationship with pulmonary metastasis in osteosarcoma. The aberrant expression of beta-catenin protein in osteosarcoma decreases or disappeares after neoadjuvant chemotherapy, to some degree, which may evaluate the efficiency of neoadjuvant chemotherapy.